CN107854585A - 一种安神定志方剂 - Google Patents
一种安神定志方剂 Download PDFInfo
- Publication number
- CN107854585A CN107854585A CN201711222658.7A CN201711222658A CN107854585A CN 107854585 A CN107854585 A CN 107854585A CN 201711222658 A CN201711222658 A CN 201711222658A CN 107854585 A CN107854585 A CN 107854585A
- Authority
- CN
- China
- Prior art keywords
- parts
- tranquilizing
- mind
- standby
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002936 tranquilizing effect Effects 0.000 title claims abstract description 37
- 241000931705 Cicada Species 0.000 claims abstract description 27
- 241000237502 Ostreidae Species 0.000 claims abstract description 24
- 235000020636 oyster Nutrition 0.000 claims abstract description 24
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 22
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 22
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 22
- 241000489492 Arisaema Species 0.000 claims abstract description 21
- 210000000941 bile Anatomy 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 244000241872 Lycium chinense Species 0.000 claims abstract description 16
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 16
- 235000004347 Perilla Nutrition 0.000 claims abstract description 16
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 15
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 15
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 15
- 239000010440 gypsum Substances 0.000 claims abstract description 15
- 244000124853 Perilla frutescens Species 0.000 claims abstract 5
- 239000007788 liquid Substances 0.000 claims description 62
- 239000000284 extract Substances 0.000 claims description 40
- 238000002156 mixing Methods 0.000 claims description 29
- 239000004615 ingredient Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 17
- 241001247821 Ziziphus Species 0.000 claims description 15
- 238000002386 leaching Methods 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 11
- 239000000796 flavoring agent Substances 0.000 claims description 11
- 235000019634 flavors Nutrition 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- 108010059892 Cellulase Proteins 0.000 claims description 8
- 229940106157 cellulase Drugs 0.000 claims description 8
- 239000003651 drinking water Substances 0.000 claims description 8
- 235000020188 drinking water Nutrition 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 229910001220 stainless steel Inorganic materials 0.000 claims description 8
- 239000010935 stainless steel Substances 0.000 claims description 8
- 239000002893 slag Substances 0.000 claims description 7
- 229920001661 Chitosan Polymers 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 229940075582 sorbic acid Drugs 0.000 claims description 5
- 235000010199 sorbic acid Nutrition 0.000 claims description 5
- 239000004334 sorbic acid Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 238000005245 sintering Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 229940100691 oral capsule Drugs 0.000 claims description 2
- 241000220324 Pyrus Species 0.000 claims 1
- 235000021017 pears Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 24
- 230000036461 convulsion Effects 0.000 abstract description 21
- 206010010904 Convulsion Diseases 0.000 abstract description 20
- 210000004556 brain Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 17
- 206010033799 Paralysis Diseases 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 6
- 206010022437 insomnia Diseases 0.000 abstract description 6
- 206010001497 Agitation Diseases 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 238000013019 agitation Methods 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000001769 paralizing effect Effects 0.000 abstract description 3
- 240000008866 Ziziphus nummularia Species 0.000 abstract 1
- 238000011160 research Methods 0.000 description 14
- 241000229722 Perilla <angiosperm> Species 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 230000001773 anti-convulsant effect Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- VCNYNWHVJKWJRQ-UHFFFAOYSA-N Isorhynchophylline Natural products CCC1=CN2CCC3(C2CC1C(=COC)C(=O)OC)C(=O)Nc4ccccc34 VCNYNWHVJKWJRQ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 229910052748 manganese Inorganic materials 0.000 description 4
- 239000011572 manganese Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010021118 Hypotonia Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229960005152 pentetrazol Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 2
- 206010013887 Dysarthria Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- IQSFEAHJUMVILC-UHFFFAOYSA-N Isorhynchophyllic acid Natural products CCC1CN2CCC3(C2CC1C(=COC)C(=O)O)C(=O)Nc4ccccc34 IQSFEAHJUMVILC-UHFFFAOYSA-N 0.000 description 2
- DAXYUDFNWXHGBE-VKCGGMIFSA-N Isorhynchophylline Chemical compound O=C1NC2=CC=CC=C2[C@]11CCN2C[C@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-VKCGGMIFSA-N 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- PLYUVYWTXHXRPG-UHFFFAOYSA-N Rhynchophyllin Natural products COC=C(/C1CCN2CCC3(CNc4ccccc34)C2C1)C(=O)OC PLYUVYWTXHXRPG-UHFFFAOYSA-N 0.000 description 2
- DAXYUDFNWXHGBE-KAXDATADSA-N Rhynchophylline Chemical compound O=C1NC2=CC=CC=C2[C@@]11CCN2C[C@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-KAXDATADSA-N 0.000 description 2
- 241000256856 Vespidae Species 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002920 convulsive effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 208000026473 slurred speech Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 241001000583 Cryptotympana atrata Species 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 240000003915 Lophatherum gracile Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000819999 Nymphes Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000028752 abnormal posture Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001535 kindling effect Effects 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000005424 photoluminescence Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及中药制剂技术领域,具体涉及一种安神定志方剂。所述安神定志按照质量配比包括蝉蜕15份、焦山楂15份、龙骨15份、牡蛎15份、钩藤10份、紫苏叶10份、地骨皮10份、大枣10份、胆南星10份、生石膏10份、防风5份、桂枝5份、甘草5份、莲子心5份。所述安神定志方剂适用于小儿惊厥、烦躁、失眠等。通过服用所述安神定志方剂,可有效提高患者机体的自我协调能力,各种原料药相互协调共用,药物之间相互协作,显著改善脏腑功能和临床自觉症状,无毒副作用、费用较低,十分对症小儿脑瘫、及中风患者。
Description
技术领域
本发明涉及中药制剂技术领域,具体涉及一种安神定志方剂。
背景技术
在现有技术中,小儿脑瘫表现形式有中枢性运动障碍和姿势异常,并有智力落后及惊厥发作、行为异常、感觉障碍及其他异常。脑瘫主要是指由于出生前、出生时、婴儿早期的某些原因造成的非进行性脑损伤所致的综合症,尽管临床症状可随年龄的增长和脑的发育成熟而发生一定改善变化,但是对于中枢神经系统的确实永久损伤的,目前治疗小儿脑瘫多采用按摩、针灸、PTOT、手术等治疗方法;
而深圳市中医院通过多年的临床经验,根据病患的发病特征、及发病原理,提出一种安神定志方剂,有效改善小儿惊厥、烦躁、失眠等病症,是医治此类疾病的有效手段。
发明内容
为了有效解决上述问题,接合中风、脑瘫的病因分析,通过长期的临床观察,发现将蝉蜕、焦山楂、龙骨、牡蛎、钩藤、紫苏叶、地骨皮、大枣、胆南星、生石膏、防风、桂枝、甘草、莲子心等中药共同研制成胶囊或口服液,让患者服用,可有效的改善脑瘫症状,提高临床治愈率和有效率。
具体配方如下,蝉蜕13-18份、焦山楂13-20份、龙骨13-20份、牡蛎13-18份、钩藤8-15份、紫苏叶8-15份、地骨皮6-13份、大枣6-15份、胆南星7-12份、生石膏6-15份、防风2-8份、桂枝3-8份、甘草2-7份、莲子心3-8份。
其中所述蝉蜕是为蝉科昆虫Cryptotympana pustulata Fabricius的若虫羽化脱落的皮壳。在夏、秋二季收集,除去泥沙,晒干而获得。蝉蜕的性状为体轻,中空,易碎。气微,味淡[中华人民共和国药典2015年版一部,中国医药科技出版社]。
研究证明,蝉蜕的药理作用具有明显的抗惊厥作用,采用95%乙醇和水对蝉蜕进行提取,制备了蝉蜕醇提物和水提物,研究两种提取物对戊四唑(PTZ)致小鼠惊厥模型的抗惊厥活性。结果证明,两种提取物均可明显延长小鼠发生惊厥的潜伏期、死亡时间,降低死亡率。其中水提物的直接抑制作用显著(降低惊厥发生率),且抗惊厥作用强度强于醇提物(对惊厥发生率无影响),推测其抗惊厥活性成分为水溶性成分。
通过蝉蜕醇提物抗惊厥作用的药效学研究发现,蝉蜕醇提物对最大电休克惊厥(MES)模型、戊四唑惊厥(MET)发作和青霉素点燃惊厥发作均有对抗作用,其作用机制是通过降低Glu的含量,限制Glu兴奋系统功能而发挥效应的。[蝉蜕的药理作用及临床应用研究进展中医药学报2015年4月第43卷第2期,文章编号:1002-2392(2015)02-0110-03]。
另外,所述杜蛎为性咸、微寒,归肝、胆、肾经,其功能与主治为重镇安神、潜阳补阴、软坚散结。用于惊悸失眠、眩晕耳鸣、瘰疬痰核、癖瘕痞块,煅牡蛎收敛固涩,制酸止痛。用于自汗盗汗,遗精滑精,崩漏带下,胃痛吞酸[中华人民共和国药典2015年版一部,中国医药科技出版社]。
所述钩藤为性甘凉。归肝、心包经。其功能与主治为息风定惊清热平肝。用于肝风内动,惊痫抽搐,高热惊厥,感冒夹惊,小儿惊惊啼,妊娠子痫,头痛眩晕[中华人民共和国药典2015年版一部,中国医药科技出版社]。研究表明,对心血管系统的作用,研究得出钩藤中降压成分主要为钩藤碱和异钩藤碱,其中以异钩藤碱的降压作用最强,其次是钩藤碱、钩藤总碱,非生物碱部分作用较弱。进一步地,研究发现钩藤能降低致痫大鼠海马脑片CAI区顺向诱发PS幅度,提示对中枢神经系统的突触传递过程有明显的抑制效应,具有抗癫痫作用[基于化学成分稳定性的钩藤药学研究进展中国中药杂志第39卷第23期2014年12月]。
所述胆南星性苦、微辛,凉。归肝、脾经。其功能与主治为清化痰、息风定惊。用于痰热咳,咯痰黄稠,中风痰迷,癫狂惊痫。胆南星的临床和药理作用为胆南星在临床上用于痰热咳嗽,咳痰黄稠,中风痰迷,癫狂惊痫等症,在药理方面,胆南星对昆明种小鼠的中枢系统有抑制作用,可增强戊巴比妥钠催眠作用,未见急性毒性反应[胆南星的研究进展中国现代中药第12卷第4期2010年4月]。
所述防风性辛、甘,微温。归膀胱、肝、脾经。其功能与主治为祛风解表,胜湿止痛,止痉。用于感冒头痛,风湿痹痛,风瘆瘙痒,破饬风。研究表明,对戊巴比妥钠阈下睡眠剂的影响和对小鼠自发活动影响实验表明,防风水煎剂有明显的镇静作用,临床应用为配息风止痉药,治破伤风,惊风及中风,用于病患牙关紧闭,小儿惊风痉挛抽搐,以及中风引起的口眼歪斜,言语蹇涩等,现代药理学以证实防风有息风定惊作用,实验表明防风液和水提物均能对抗电刺激引起的动物惊厥或使惊厥发,生期延长[中药防风的研究进展井冈山医专学报第11卷第4期2004年7月]。
所述甘草性甘,平。归心、肺、脾、胃经,其功能与主治为补脾益气,淸热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳痰,脘腹、四肢挛急,疼痛,痈肿疮毒,缓解药物毒性、烈性。研究表明,所述甘草具有降脂作用及抗动脉粥样硬化作用,甘草甜素能促使胆固醇含量降低,磷脂质明显下降,抑制机体和血管壁的炎症反应,防止动脉粥样硬化的发生及发展。甘草酸有明显的降脂作用,能阻止大动脉及冠状动脉粥样硬化的发展。甘草酸盐可抑制血小板的凝集作用[甘草中化学成分的研究吉林大学硕士学位论文单位代码10183研究生学号2003772037]。
所述莲子心性苦。归心、肾经,其功能与主治为清心安神,交通心肾,涩精止血。用于热入心包,神昏谵语,心肾不交,失眠遗精,血热吐血。研究表明,莲子心临床应用于神经、精神系统疾病,治疗癫、狂、痫等精神病主张在镇心安神的基础上,从疏肝解郁、涤痰清热着手,莲子心为其常用药,取其清心辟秽作用;小儿神经性尿频,武春丽等[17]认为小儿阳常有余而阴常不足,心火易亢,更由于多食肥甘膏粱厚味,致使多数神经性尿频患儿出现心脾蕴热的表现,故选用导赤散加减治疗小儿神经性尿频26例,以莲子心合淡竹叶清心除烦,连翘、甘草梢清上泻下,生地黄凉血滋阴以制心火,共奏清心泻热、清利小肠之效,总有效率为96.15%。
进一步地,莲子心临床用于小儿抽动-秽语综合征,临床以复杂的慢性神经精神疾病为特征,多表现有不自主眨眼、皱鼻、撅嘴、伸颈、耸肩、清嗓声、吭吭声,或易于激惹,或伴有夜睡磨牙、容易汗出等症状[莲子心的现代临床应用长春中医药大学学报第28卷第3期2012年6月文章编号1007-4813(2012)03-0544-03]。
优选为,所述安神定志按照质量配比包括蝉蜕15份、焦山楂15份、龙骨15份、牡蛎15份、钩藤10份、紫苏叶10份、地骨皮10份、大枣10份、胆南星10份、生石膏10份、防风5份、桂枝5份、甘草5份、莲子心5份。
其中蝉蜕、龙骨、杜蛎的按质量比例为1:1:0.7-1.5,进行配比,共同制备入药,其中有研究显示牡蛎壳和龙骨的含量分别为39.78%±0.23%,31.98%±0.14%;两者均含有Cu、Fe、Zn、Mn、Sr、Cr、Ni、Pb、Hg,9种微量元素。除了牡蛎壳中铁、铅和汞种元素的量较龙骨少外其余微量元素没有明显差别。另外有研究显示龙骨无论生品、煅品其微量元素Zn、Cu、Mn、Fe、Cd、Na、K的含量均比牡蛎低。但龙骨与牡蛎混合后,微量元素含量大大增加,这正是龙骨与牡蛎常一同使用的原因。
两者共同使用的临床应用于镇静、解痉、抗惊厥作用:可参与神经冲动的传递和神经肌肉应激性的维持等生理功能活动它可使运动神经末稍乙酰胆碱释放减少具有中枢抑制和骨骼肌松弛作用。对调节中枢神经系统的功能有着重要的作用;可增强神经末梢对去甲肾上腺素(NE)的再吸收,或减少NE与突触后膜的接触结合对中枢神经递质产生影响,因而有较好的镇静、催眠与抗惊厥作用。
龙骨牡蛎配伍乃中药平肝潜阳之重要药对。有研究显示生龙牡煎液中、含量高于锻龙牡煎液。中医认为肝阳上亢之证可滋肾水以抑之即滋水涵木法。研究表明在肝、肾中的分布量最高,肾阴虚多采用含锰较高的中药进行治疗。是体内血红蛋白的氧的携带体能补益肝肾阴血。故龙骨牡蛎生用平肝潜阳之力强,与其中Mn、Fe含量较高有关[《伤寒杂病论》中龙骨、牡蛎的应用及配伍规律探索广州中医药大学硕士学位论文学校代号10572时间2012年4月]。
龙骨与杜蛎共同使用,按最佳的配比发挥两者药物效果,而蝉蜕与龙骨、杜蛎的共同使用,对于脑瘫患者产生的惊厥、痉挛等微量元素失衡引起的并发症,具有明显的临床治愈效果。
优选为,所述中药方剂按照常规工艺,添加常规辅料,制成临床上可接受的内服制剂;
所述内服制剂为口服液。
一种安神定志的口服液的制备方法,所述制备方法包括以下工序:
(1)备料:
按质量配比,称取优质的主料:蝉蜕、牡蛎、钩藤、胆南星、防风、甘草、莲子心,洗净并除杂,备用;
按质量配比,称取优质的辅料:焦山楂、龙骨、紫苏叶、地骨皮、大枣、生石膏、桂枝,洗净并除杂,备用;
在国家标准规定范围内的称取适当优质的调味剂、防腐剂,备用;
(2)浸提:
主料浸提:取备用的蝉蜕、牡蛎、钩藤、胆南星、防风、甘草、莲子心,分别置于煎煮容器内部进行煎煮提取,分别提取二次后,混合两次提取液;得到不同主料的提取液,备用;
辅料浸提:取备用的焦山楂、龙骨、紫苏叶、地骨皮、大枣、生石膏、桂枝,混合置于煎煮容器内部,加入12-15倍饮用水,煎煮2-3小时,经80-100目滤网,取汁留渣,得第一次滤液;取残渣加入2-3倍水,煎煮1-2小时,过滤得第二次滤液,残渣备用;合并两次滤液,得辅料混合浸提液;
(3)混合:
预混合:取备用的不同主料的提取液,置于混合容器内混合搅拌均匀,在混合搅拌过程中,持续低温加热,得主料混合浸提液;
总混:取备用的辅料混合浸提液,加入主料混合浸提液,置于混合容器内部混合搅拌均匀,在混合搅拌过程中,持续低温加热,冷却后,得总混液;
(4)酶解:
取总混液,加入纤维素酶,在40-45℃条件下,酶解1-1.5小时,得第一次酶解液;去除残渣,获得第一次酶解液,再加入1-3倍饮用水,在加入纤维素酶,在40-45℃条件下,酶解0.5-1小时,过滤后得第二次酶解液;合并两次酶解液,得混合酶解液;
(5)离心过滤:
取混合酶解液,静置8-10小时,放入离心机内,3000-3500r/min离心过滤10-15分钟,获得离心液;
(6)浓缩:
取离心液,置于真空浓缩机内,浓缩至相对密度为95-98%的口服液原液;
(7)灭菌:
取口服液原液,加入防腐剂、调味剂,混合均匀后,经热压法灭菌,分装,得成品。
优选为,所述工序(2)浸提中,主料浸提中,分别提取二次的过程中:第一次提取加入原料10-12倍的纯净水,中火提取1.5-2小时;第二次提取加入原料6-8倍的水,大火提取0.5小时。
优选为,所述防腐剂为山梨酸,所述调味剂为壳聚糖
优选为,所述安神定志方剂还可制备为所述内服制剂为口服胶囊。
优选为,所述安神定志方剂还可制备为所述内服制剂为口服冲剂。
有益之处:所述安神定志方剂适用于小儿惊厥、烦躁、失眠等。各种原料药相互协调共用,药物之间相互协作,起到最大程度发挥药效。中医学认为小儿脑瘫:脑为元神之府,导致智力低下,反应迟钝,语言不清,咀嚼无力,时流涎水,四肢无力,手软不能握持,足软不能站立。或感受热毒,损伤脑络,后期耗气伤阴,脑髓及四肢百骸、筋肉失养,导致本病。通过服用所述安神定志方剂,可有效提高患者机体的自我协调能力,显著改善脏腑功能和临床自觉症状,无毒副作用、费用较低,十分对症小儿脑瘫、及中风患者。
附图说明
图1为本发明所述安神定志的口服液的制备方法流程图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实施例,对本发明进行进一步详细描述。应当理解,此处所描述的具体实施例仅仅用于解释本发明,并不用于限定本发明。
相反,本发明涵盖任何由权利要求定义的在本发明的精髓和范围上做的替代、修改、等效方法以及方案。进一步,为了使公众对本发明有更好的了解,在下文对本发明的细节描述中,详尽描述了一些特定的细节部分。对本领域技术人员来说没有这些细节部分的描述也可以完全理解本发明。
在本发明第一实施例中,所述实施例提供了一种安神定志方剂,所述蝉蜕13份、焦山楂13份、龙骨13份、牡蛎13份、钩藤8份、紫苏叶8份、地骨皮6份、大枣6份、胆南星7份、生石膏6份、防风2份、桂枝3份、甘草2份、莲子心3份。
所述中药方剂按照常规工艺,添加常规辅料,制成临床上可接受的内服制剂;所述内服制剂为口服液。
一种安神定志的口服液的制备方法,所述制备方法包括以下工序:
(1)备料:
按质量配比,称取优质的主料:蝉蜕、牡蛎、钩藤、胆南星、防风、甘草、莲子心,洗净并除杂,备用;
按质量配比,称取优质的辅料:焦山楂、龙骨、紫苏叶、地骨皮、大枣、生石膏、桂枝,洗净并除杂,备用;
在国家标准规定范围内的称取适当优质的调味剂、防腐剂,备用;
(2)浸提:
主料浸提:取备用的蝉蜕、牡蛎、钩藤、胆南星、防风、甘草、莲子心,分别置于煎煮容器内部进行煎煮提取,分别提取二次后,混合两次提取液;得到不同主料的提取液,备用;
辅料浸提:取备用的焦山楂、龙骨、紫苏叶、地骨皮、大枣、生石膏、桂枝,混合置于煎煮容器内部,加入12倍饮用水,煎煮2小时,经80目滤网,取汁留渣,得第一次滤液;取残渣加入2倍水,煎煮1小时,过滤得第二次滤液,残渣备用;合并两次滤液,得辅料混合浸提液;
(3)混合:
预混合:取备用的不同主料的提取液,置于混合容器内混合搅拌均匀,在混合搅拌过程中,持续低温加热,得主料混合浸提液;
总混:取备用的辅料混合浸提液,加入主料混合浸提液,置于混合容器内部混合搅拌均匀,在混合搅拌过程中,持续低温加热,冷却后,得总混液;
(4)酶解:
取总混液,加入纤维素酶,在40-45℃条件下,酶解1小时,得第一次酶解液;去除残渣,获得第一次酶解液,再加入2倍饮用水,在加入纤维素酶,在40-45℃条件下,酶解0.5小时,过滤后得第二次酶解液;合并两次酶解液,得混合酶解液;
(5)离心过滤:
取混合酶解液,静置8-10小时,放入离心机内,3000r/min离心过滤10分钟,获得离心液;
(6)浓缩:
取离心液,置于真空浓缩机内,浓缩至相对密度为95-98%的口服液原液;
(7)灭菌:
取口服液原液,加入山梨酸、壳聚糖,其中山梨酸作为防腐剂,壳聚糖作为调味剂,混合均匀后,经热压法灭菌,分装,得成品。
在本发明的第二实施中,所述实施例提供了一种安神定志方剂,所述安神定志方剂包括蝉蜕18份、焦山楂20份、龙骨20份、牡蛎18份、钩藤15份、紫苏叶15份、地骨皮13份、大枣15份、胆南星12份、生石膏15份、防风8份、桂枝8份、甘草7份、莲子心8份。
按上述的质量配比,应用所述一种安神定志的口服液的制备方法,制备安神定志口服液。
(1)备料:
按质量配比,称取优质的主料:蝉蜕、牡蛎、钩藤、胆南星、防风、甘草、莲子心,洗净并除杂,备用;
按质量配比,称取优质的辅料:焦山楂、龙骨、紫苏叶、地骨皮、大枣、生石膏、桂枝,洗净并除杂,备用;
在国家标准规定范围内的称取适当优质的调味剂、防腐剂,备用;
(2)浸提:
主料浸提:取备用的蝉蜕、牡蛎、钩藤、胆南星、防风、甘草、莲子心,分别置于煎煮容器内部进行煎煮提取,分别提取二次后,混合两次提取液;得到不同主料的提取液,备用;
辅料浸提:取备用的焦山楂、龙骨、紫苏叶、地骨皮、大枣、生石膏、桂枝,混合置于煎煮容器内部,加入15倍饮用水,煎煮3小时,经100目滤网,取汁留渣,得第一次滤液;取残渣加入3倍水,煎煮2小时,过滤得第二次滤液,残渣备用;合并两次滤液,得辅料混合浸提液;
(3)混合:
预混合:取备用的不同主料的提取液,置于混合容器内混合搅拌均匀,在混合搅拌过程中,持续低温加热,得主料混合浸提液;
总混:取备用的辅料混合浸提液,加入主料混合浸提液,置于混合容器内部混合搅拌均匀,在混合搅拌过程中,持续低温加热,冷却后,得总混液;
(4)酶解:
取总混液,加入纤维素酶,在40-45℃条件下,酶解1.5小时,得第一次酶解液;去除残渣,获得第一次酶解液,再加入3倍饮用水,在加入纤维素酶,在40-45℃条件下,酶解1小时,过滤后得第二次酶解液;合并两次酶解液,得混合酶解液;
(5)离心过滤:
取混合酶解液,静置10小时,放入离心机内,3500r/min离心过滤15分钟,获得离心液;
(6)浓缩:
取离心液,置于真空浓缩机内,浓缩至相对密度为95-98%的口服液原液;
(7)灭菌:
取口服液原液,加入山梨酸、壳聚糖,混合均匀后,经热压法灭菌,分装,得成品。
优选为,所述工序(2)浸提中,主料浸提中,分别提取二次的过程中:第一次提取加入原料12倍的纯净水,中火提取2小时;第二次提取加入原料8倍的水,大火提取0.5小时。
在本发明的第三实施例中,所述安神定志方剂按照所述中药方剂按照常规工艺,添加常规辅料,制成临床上可口服的胶囊。
在本发明的第四实施例中,所述安神定志方剂按照所述中药方剂按照常规工艺,添加常规辅料,制成临床上可口服的口服冲剂。
所述安神定志方剂适用于小儿惊厥、烦躁、失眠等。各种原料药相互协调共用,药物之间相互协作,起到最大程度发挥药效。中医学认为小儿脑瘫:脑为元神之府,导致智力低下,反应迟钝,语言不清,咀嚼无力,时流涎水,四肢无力,手软不能握持,足软不能站立。或感受热毒,损伤脑络,后期耗气伤阴,脑髓及四肢百骸、筋肉失养,导致本病。通过服用所述安神定志方剂,可有效提高患者机体的自我协调能力,显著改善脏腑功能和临床自觉症状,无毒副作用、费用较低,十分对症小儿脑瘫、及中风患者。
对于本领域的普通技术人员而言,根据本发明的教导,在不脱离本发明的原理与精神的情况下,对实施方式所进行的改变、修改、替换和变形仍落入本发明的保护范围之内。
Claims (8)
1.一种安神定志方剂,其特征在于,所述安神定志方剂按照质量配比包括:
蝉蜕13-18份、焦山楂13-20份、龙骨13-20份、牡蛎13-18份、钩藤8-15份、紫苏叶8-15份、地骨皮6-13份、大枣6-15份、胆南星7-12份、生石膏6-15份、防风2-8份、桂枝3-8份、甘草2-7份、莲子心3-8份。
2.根据权利要求1所述一种安神定志方剂,其特征在于,所述安神定志按照质量配比包括蝉蜕15份、焦山楂15份、龙骨15份、牡蛎15份、钩藤10份、紫苏叶10份、地骨皮10份、大枣10份、胆南星10份、生石膏10份、防风5份、桂枝5份、甘草5份、莲子心5份。
3.根据权利要求1所述一种安神定志方剂,其特征在于,所述中药方剂按照常规工艺,添加常规辅料,制成临床上可接受的内服制剂;
所述内服制剂为口服液。
4.一种安神定志的口服液的制备方法,其特征在于,所述口服液应用权利要求1所述安神定志方剂的质量配比进行制备,所述制备方法包括以下工序:
(1)备料:
按质量配比,称取优质的主料:蝉蜕、牡蛎、钩藤、胆南星、防风、甘草、莲子心,洗净并除杂,备用;
按质量配比,称取优质的辅料:焦山楂、龙骨、紫苏叶、地骨皮、大枣、生石膏、桂枝,洗净并除杂,备用;
在国家标准规定范围内的称取适当优质的调味剂、防腐剂,备用;
(2)浸提:
主料浸提:取备用的蝉蜕、牡蛎、钩藤、胆南星、防风、甘草、莲子心,分别置于煎煮容器内部进行煎煮提取,分别提取二次后,混合两次提取液;得到不同主料的提取液,备用;
辅料浸提:取备用的焦山楂、龙骨、紫苏叶、地骨皮、大枣、生石膏、桂枝,混合置于煎煮容器内部,加入12-15倍饮用水,煎煮2-3小时,经80-100目滤网,取汁留渣,得第一次滤液;取残渣加入2-3倍水,煎煮1-2小时,过滤得第二次滤液,残渣备用;合并两次滤液,得辅料混合浸提液;
(3)混合:
预混合:取备用的不同主料的提取液,置于混合容器内混合搅拌均匀,在混合搅拌过程中,持续低温加热,得主料混合浸提液;
总混:取备用的辅料混合浸提液,加入主料混合浸提液,置于混合容器内部混合搅拌均匀,在混合搅拌过程中,持续低温加热,冷却后,得总混液;
(4)酶解:
取总混液,加入纤维素酶,在40-45℃条件下,酶解1-1.5小时,得第一次酶解液;去除残渣,获得第一次酶解液,再加入1-3倍饮用水,在加入纤维素酶,在40-45℃条件下,酶解0.5-1小时,过滤后得第二次酶解液;合并两次酶解液,得混合酶解液;
(5)离心过滤:
取混合酶解液,静置8-10小时,放入离心机内,3000-3500r/mi n离心过滤10-15分钟,获得离心液;
(6)浓缩:
取离心液,置于真空浓缩机内,浓缩至相对密度为95-98%的口服液原液;
(7)灭菌:
取口服液原液,加入防腐剂、调味剂,其中山梨酸作为防腐剂,壳聚糖作为调味剂,混合均匀后,经热压法灭菌,分装,获得成品。
5.根据权利要求4所述一种安神定志方剂,其特征在于,所述工序(2)的主料浸提中,分别提取二次的过程中:第一次提取加入原料10-12倍的纯净水,中火提取1.5-2小时;第二次提取加入原料6-8倍的水,大火提取0.5小时。
6.根据权利要求4所述一种安神定志方剂,其特征在于,所述工序(7)中的防腐剂为山梨酸,所述调味剂为壳聚糖。
7.根据权利要求3所述一种安神定志方剂,其特征在于,所述内服制剂为口服胶囊。
8.根据权利要求3所述一种安神定志方剂,其特征在于,所述内服制剂为口服冲剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711222658.7A CN107854585A (zh) | 2017-11-29 | 2017-11-29 | 一种安神定志方剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711222658.7A CN107854585A (zh) | 2017-11-29 | 2017-11-29 | 一种安神定志方剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107854585A true CN107854585A (zh) | 2018-03-30 |
Family
ID=61704245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711222658.7A Pending CN107854585A (zh) | 2017-11-29 | 2017-11-29 | 一种安神定志方剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107854585A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8110228B2 (en) * | 2005-04-01 | 2012-02-07 | Bionovo, Inc. | Composition for treatment of menopause |
-
2017
- 2017-11-29 CN CN201711222658.7A patent/CN107854585A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8110228B2 (en) * | 2005-04-01 | 2012-02-07 | Bionovo, Inc. | Composition for treatment of menopause |
Non-Patent Citations (5)
Title |
---|
吴卫: "酶解法辅助提取钩藤中钩藤碱的工艺优选", 《中国实验方剂学杂志》 * |
尹绍锴: "于海波治疗小儿多发性抽动症经验", 《广州中医药大学学报》 * |
康明: "浅析中医安神治法", 《内蒙古中医药》 * |
李梅: "《中医药学基础》", 31 August 2009, 中国医药科技出版社 * |
顾平: "中药复方治疗心悸用药规律分析", 《中国中医基础医学杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103859379A (zh) | 一种有助于改善记忆的养生保健食品配方及其制备方法 | |
CN102687773A (zh) | 一种养肝保健茶 | |
CN108926702A (zh) | 一种用于调理亚健康状态的中草药配方及其制备方法 | |
CN103330021B (zh) | 一种养生茶 | |
CN103609992A (zh) | 一种高丽红参膏的制备方法 | |
CN102895349A (zh) | 一种治疗高血压、高血脂、高血糖的中药茶 | |
CN106236875B (zh) | 一种清肝明目的中药组合物及其制备方法 | |
CN105505727A (zh) | 一种明目提神的醋饮 | |
CN103005594A (zh) | 一种饮料 | |
CN104474099B (zh) | 一种甜茶止咳露及其制备方法 | |
CN101112605A (zh) | 一种黑豆美容养颜暖醋 | |
CN105861252A (zh) | 一种灵芝保健米酒 | |
CN105331477A (zh) | 一种白葡萄酒及其制备方法 | |
CN107854585A (zh) | 一种安神定志方剂 | |
CN1259969C (zh) | 一种补脑益智胶囊及其制备工艺 | |
CN105998639A (zh) | 一种降脂降压饮液及其制备方法 | |
CN105410926A (zh) | 一种长茎葡萄蕨藻减肥胶囊及其制备方法 | |
CN110584037A (zh) | 一种食品人参膏及其制备方法 | |
CN103845670A (zh) | 治疗冠状动脉粥样硬化的冲剂及制备方法 | |
CN108159191A (zh) | 壮阳健肾的组合物、用途和口服液及其制备方法 | |
CN103816426B (zh) | 一种治疗风毒入里证型破伤风病的中药 | |
CN108142604A (zh) | 一种降血压保健果茶及其制备方法 | |
CN109106842B (zh) | 一种用于戒烟的药物及其制备方法 | |
KR20100035961A (ko) | 산양산삼 분말을 함유하는 공진단 조성물 | |
CN105494768A (zh) | 润肺祛痰保健茶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180330 |
|
WD01 | Invention patent application deemed withdrawn after publication |